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Abstract
Background: Recent studies indicate that angiogenesis is important in the pathogenesis of acute myeloid leukemias
(AMLs). Among the various AMLs, the bone marrow angiogenetic response is particularly pronounced in acute
promyelocytic leukemia (APL). However, the molecular mechanisms responsible for this angiogenetic response are
largely unknown. In the present study, we have explored the role of HHEX, a homeodomain transcription factor, as a
possible mediator of the pro-angiogenetic response observed in APL. This transcription factor seems to represent an
ideal candidate for this biologic function because it is targeted by PML-RARα, is capable of interaction with PML and
PML-RARα, and acts as a regulator of the angiogenetic response.
Methods: We used various cellular systems of APL, including primary APL cells and leukemic cells engineered to
express PML-RARα, to explore the role of the PML-RARα fusion protein on HHEX expression. Molecular and biochemical
techniques have been used to investigate the mechanisms through which PML-RARα downmodulates HHEX and the
functional consequences of this downmodulation at the level of the expression of various angiogenetic genes, cell
proliferation and differentiation.
Results: Our results show that HHEX expression is clearly downmodulated in APL and that this effect is directly
mediated by a repressive targeting of the HHEX gene promoter by PML-RARα. Studies carried out in primary APL
cells and in a cell line model of APL with inducible PML-RARα expression directly support the view that this fusion
protein through HHEX downmodulation stimulates the expression of various genes involved in angiogenesis and
inhibits cell differentiation.
Conclusions: Our data suggest that HHEX downmodulation by PML-RARα is a key event during APL pathogenesis.
Background
The hematopoietic expressed homeobox gene (HHEX),
also known as proline-rich homeodomain (PRH), is a
transcription factor containing the DNA-binding domain
termed the homeodomain. Similarly to the homeobox
proteins, HHEX regulates cell development and differenti-
ation, being required for the formation of the vertebrate
body axis and the hematopoietic and vascular systems [1].
HHEX−/− mice display embryonic lethality due to im-
paired forebrain, liver, and thyroid development; these
mice display also defective vasculogenesis and elevated
VEGF-A levels [2, 3].
HHEX is expressed in areas of the mammalian embryos
that mainly contribute to hematopoietic and vascular de-
velopment [1]. In particular, HHEX expression is seen very
early during embryonic development in the blood islands
of the yolk sac [4]. HHEX is highly expressed in stem cells
and myeloid and lymphoid progenitors and its expression
is maintained in adult hematopoietic tissues at the level
of several blood cell lineages, including hematopoietic
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progenitors, lymphocytes, and myeloid lineages [5, 6].
Importantly, HHEX expression was found to be down-
regulated during terminal differentiation of both B
cells [1] and myeloid cells [7]. In fact, using Myb-Ets-
transformed chicken blastoderm cells (MEPs), it was
shown that HHEX RNA and protein levels are down-
regulated when MEPs differentiate along the myelomo-
nocytic and erythrocytic lineages, while they are maintained
when these cells differentiate toward the thrombocytic
lineage [7]. Furthermore, HHEX expression is downmo-
dulated also in the T-cell lineage and this downregulation
is physiologically critical since HHEX overexpression in
these cells determines the development of T-cell leukemia
in mice [8]. Using various embryonic stem cell differenti-
ation models, it was possible to show that HHEX is re-
quired for proliferation and differentiation of definitive
HSCs [9–11]. Particularly, Paz and coworkers have shown
that HHEX−/− embryonic stem cells when triggered to
hematopoietic differentiation display the accumulation
of early hematopoietic progenitors CD41+c-kit+ and a
reduced capability to generate myeloid hematopoietic
colonies, such as BFU-Mix, BFU-E, and CFU-GM [11].
Few studies have explored the expression and a pos-
sible deregulation of HHEX in leukemic cells. HHEX
was expressed in the large majority of leukemic cell lines
and its expression is usually lost when these cell lines
are induced to differentiate [12]. In some rare AML pa-
tients, it was reported that a specific double transloca-
tion involving nucleoporin 98 was fused to the DNA-
binding domain of the HHEX transcription factor [13].
The mechanism resulting in leukemia in these patients
is not known, but it was proposed that the fusion pro-
tein may compete with endogenous HHEX for HHEX
targets and may derepress genes normally blocked by
HHEX [13].
Importantly, HHEX was shown to interact with the pro-
myelocytic leukemia protein (PML) in various leukemic
cell lines, including the promyelocytic cell line NB4 [14].
Yeast two-hybrid experiments have shown that HHEX
was capable of directly interacting with PML across its
ring finger domain, which is required for the protein activ-
ity in the control of cell growth [14]. Furthermore, HHEX
was shown to be able to interact also with the PML-RARα
oncoprotein that characterizes acute promyelocytic leuke-
mias (APLs) [14]. According to these observations, it was
proposed that disruption not only of PML but also of
HHEX functions by PML-RARα fusion protein may
play a relevant role in the pathogenesis of APLs [14]. In
an attempt to define the mechanism through which
PML-RARα blocks myeloid differentiation at the promye-
locytic stage, Wang and coworkers have shown that
PML-RARα targets promoter regions containing PU.1
consensus and RARE half sites in APL cells [15]. Among
the various gene promoters displaying these characteristics,
there is also the HHEX promoter, seemingly repressed by
PML/RARα binding [15]. PML-RARα-mediated repression
of PU.1-mediated transactivation was restored by the
addition of all-trans retinoic acid (ATRA). The key
functional role of PML-RARα-mediated repression of
PU.1 expression and function was carefully confirmed
by the same authors in other studies [16, 17].
Given the key role of HHEX in the control of
hematopoietic cell differentiation, the targeting of the
HHEX gene by the fusion oncoprotein PML-RARα, and
the capacity of the HHEX protein to interact with PML
and PML-RARα, we sought to investigate the expression
and the possible deregulation of HHEX in APLs. In the
present study, we have explored the expression and the
deregulation of HHEX in APL. Our results indicate that
HHEX expression is clearly downmodulated in APLs,
while VEGF-A expression is upregulated. The study of
an APL cell line model with inducible PML-RARα expres-
sion supports the view that this fusion protein significantly
downmodulates HHEX expression. The inhibitory effect
exerted by PML-RARα on HHEX expression seems to be
physio-pathologically relevant to mediate the inhibitory
effect on cell differentiation and the pro-angiogenetic
effect induced by this fusion protein.
Results
HHEX expression is downmodulated during granulocytic
differentiation
In a previous study, Wang and coworkers have shown
that PML/RARα acts as a potent repressor of PU.1-
RARE binding sites present at the level of various genes,
including HHEX gene; this repression was relieved by
all-trans retinoic acid (ATRA) [15]. Given the key role of
HHEX as a repressor of various angiogenetic genes and
the elevated expression of angiogenetic factors in APL, it
seemed of interest to explore in detail the possible con-
sequences of a deregulated HHEX expression in APLs
induced by PML-RARα.
Thus, in a first set of experiments, we evaluated
HHEX messenger RNA (mRNA) expression by real-time
PCR in human CD34+ cells triggered to selective granulo-
cytic differentiation under appropriate and selective cell
culture conditions. HHEX was clearly expressed in undif-
ferentiated CD34+ progenitors and its expression progres-
sively and continuously decreased during the process of
granulocytic differentiation and maturation (Fig. 1a).
HHEX expression is downmodulated in APLs
We then compared the level of HHEX mRNA expression
observed in either normal CD34+ cells or day 7 granulo-
cytic cells, composed by a majority of normal promyelo-
cytes, with the HHEX mRNA levels observed in fresh
diagnostic APL blasts and we observed that HHEX levels
were markedly lower in leukemic cells than in their normal
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counterpart (Fig. 1b). In APL fresh leukemic blasts induced
in vitro to terminal granulocytic differentiation, a further
decrease of HHEX RNA expression was observed, its ex-
pression being virtually absent in terminally differentiated
APL cells (i.e., at 120 h after ATRA addition) (Fig. 1c).
ATRA also induced a marked downmodulation of the ex-
pression of various angiogenetic genes, including VEGF-R2
(Fig. 1d).
In a second set of experiments, we evaluated the ex-
pression of HHEX and of several angiogenetic genes,
including VEGF-A, VEGF-R2, angiopoietin-1, Tie-2, and
FGFR-1, in APL fresh blasts derived from 18 patients. The
majority of these angiogenetic genes and, particularly,
VEGF-A, Tie-2, and FGFR-1 were frequently expressed in
APL cells, while HHEX was scarcely expressed in all
APL patients, compared to normal CD34+ cells (Fig. 2).
However, it is worth noting that HHEX levels are
heterogeneous in distinct APL patients and we hypothe-
sized a possible negative correlation between HHEX
and VEGF-A levels. The plotting of individual HHEX
and VEGF-A levels showed the existence of a negative
correlation between these two parameters (p < 0.04).
In order to determine whether low HHEX expression
levels were restricted to specific FAB AML subtypes, the
RNA seq data from TCGA samples were correlated with
each FAB subtype. Within each FAB category, the sam-
ples were ordered according to the expression levels of
respectively HHEX and VEGF-A transcripts (Additional
file 1: Figure S1A). This analysis showed that (a) among
the various AMLs, M3 (APLs), M4, and M5 are those
expressing the lowest HHEX levels, compared to M0,
M1, and M2 AMLs; (b) the levels of VEGF-A expression
were much higher in M3 than in all the other FAB AML
subtypes; (c) the HHEX/VEGF-A ratio was much lower
Fig. 1 HHEX expression during granulocytic differentiation of normal CB CD34+ cells (a, b) and of primary APL cells (b, c); expression of angiopoietic
growth receptors (VEGF-R2 and Tie-2) and ligands (VEGF and angiopoietin-1) in APL primary cells induced to granulocytic differentiation (d, e). Normal
CD34+ cells have been purified from cord blood and grown in vitro under cell culture conditions allowing their selective granulocytic differentiation; at
different days of culture, cell aliquots were harvested and processed for HHEX expression by real-time PCR analysis. Primary leukemic APL blasts were
purified from the bone marrow of an APL patient and grown in vitro in cell culture medium containing 1 μM ATRA, harvested at different times and
processed for HHEX, VEGF, VEGF-R2, Tie-2, and angiopoietin-1 expression by real-time PCR
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in M3 than in the other FAB AML subtypes; (d) the
plotting of the individual HHEX and VEGF-A levels in
M3 AML patients showed the existence of a significant
negative correlation between these two parameters (p <
0.028) (Additional file 1: Figure S1B). Since HHEX levels
were particularly low in M5 AMLs, it was of interest to
verify whether there is also among these AMLs and in-
verse relationship between HHEX and VEGF-A levels.
The results of this analysis showed the existence of a
significant negative correlation between HHEX and
VEGF-A levels (Additional file 1: Figure S1C).
PML-RARα downmodulates HHEX expression
In order to evaluate the molecular mechanisms through
which PML-RARα induces a downmodulation of HHEX
expression and the possible functional consequences of
this downmodulation, we have used as an experimental
tool U-937 cells transfected with PML-RARα (clone
PR9) [18]. In line with a previous report [15], CHIP
experiments showed that PR9 cells treated with Zn2+
PML-RARα were able to bind at the level of a RARα
binding site present in the HHEX gene regulatory re-
gion (first exon) (Fig. 3b). In a preliminary experiment,
we have shown that the activation of PML-RARα ex-
pression in PR9 cells (in these cells, the PML-RARα
gene is under the control of the metallothionein pro-
moter; and thus, its expression is inducible by Zn2+
addition) induced by Zn2+ addition resulted in a marked
decline of HHEX expression (Fig. 3b), paralleled by a
concomitant induction of the expression of angiogenetic
genes, such as VEGFR-2: at day 4 after Zn2+ addition,
HHEX expression was virtually undetectable at mRNA
level and very low at protein level, compared to the levels
observed in control untreated PR9 cells (Fig. 3c, d). In
Fig. 2 Analysis of HHEX, VEGF-A, VEGFR-2, FGFR1, Tie-2, and Angp-1 mRNA levels in normal CB CD34+ cells and in leukemic blasts of 18 primary APLs.
The expression levels of the mRNA of these genes were evaluated by real-time PCR, and the results reported in the figure represent the mean ± SEM
values observed for individual analyses repeated three times
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order to provide more direct evidence that the downmo-
dulation of HHEX observed in Zn2+-treated cells was
really related to PML/RARα expression, we have treated
PR9 cells with Zn2+ and arsenic trioxide (ATO), an agent
promoting PML-RARα degradation (Fig. 4a). These ex-
periments showed that ATO added together with Zn2+
completely prevented the Zn2+-induced HHEX down-
modulation in PR9 cells (Fig. 4a, b). The causal link be-
tween PML-RARα expression and low HHEX expression
was further reinforced by the observation that treatment
of NB4 cells with ATO elicited a pronounced upmodula-
tion of HHEX expression (Fig. 4c). Thus, PR9 cells seemed
to be a suitable model to explore the modulation of
HHEX expression by PML-RARα.
We then evaluated whether the reduced HHEX ex-
pression induced by PML-RARα determines a reduced
capacity of this transcription factor to bind at the level
of target gene promoters. Thus, gel shift experiments
were carried out using as target two putative HHEX
binding sequences, containing core 5′-ATTA-3′ motifs,
observed at the level of the VEGFR-2 promoter, which
are located approximately 1.1 Kb upstream of the first
exon. Cell extracts derived from PR9 cells incubated
with labeled oligonucleotides corresponding to these
sequences were shown to be capable to form two spe-
cific bands that were competed by 200 fold excess of
cold oligonucleotides (Fig. 5a). The intensity of these
two bands decreased in gel shift assays performed using
cell extracts derived from Zn2+-treated cells, compared
to untreated cells; a normal binding activity was ob-
served in cell extracts derived from cells incubated with
Zn2+ and ATRA (Fig. 5a).
To provide further evidence that HHEX was able to
bind to VEGF and VEGFR-2 promoter and that its DNA-
binding capacity was downmodulated by PML-RARαwe
carried out chromatin immunoprecipitation experiments
(CHIP). A genomic region of about 500–600 bp con-
taining the HHEX binding sequence in the VEGF or
the VEGFR-2 promoter was amplified in the immuno-
precipitates by PCR using specific primers flanking the
HHEX binding motif. In the presence of a control IgG
(-Ab), no PCR product was produced. In the presence
of anti-HHEX antibody, the CHIP experiments
showed that under control, unstimulated conditions,
the VEGF and VEGFR-2 promoters are occupied by
HHEX; this binding markedly declines in PR9 cells
grown for 12 h in the presence of 100 μM ZnSO4
(Fig. 5b, c)
Fig. 3 Effect of PML/RARα induction on the binding of PML-RARα to the HHEX gene promoter and on the expression of VEGF-A, VEGFR-2, and
HHEX at RNA and at protein level. a PML-RARα binding to the HHEX promoter as shown by ChIP experiments. Nuclear extracts derived from PR9
cells grown for 24 h either in the absence (c) or in the presence of ZnSO4 (Zn
2+); cells were crosslinked in vivo; after cell lysis, chromatin fragments
were immunoprecipitated with anti-RARα antibody; and after DNA purification, DNA regions containing HHEX were amplified. In the figure, the HHEX
PCR signal without immunoprecipitation is indicated as −A (IgG control) and, after immunoprecipitation, as +A (RARα antibody). b, c, d ZnSO4(Zn2+)
was added to PR9 cells and, at different time points and concentrations, cell aliquots were harvested and processed for evaluation of PML-RARα
expression at protein level (b) and of VEGF-A, VEGFR-2, and HHEX expression at RNA level by RT-PCR (c) and at protein level by Western blotting
(d). S26 was used for RT-PCR and β-actin for Western blotting normalization
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HHEX downmodulation is required for the growth-
promoting, pro-angiogenetic, and differentiation blocking
effects mediated by PML-RARα
In a last set of experiments, we have evaluated the pos-
sible functional consequences of PML-RARα-induced
HHEX downmodulation in the context of the leukemic
cell phenotype. To this end, we have used a specific
small interfering RNA (siRNA) to downmodulate HHEX
expression into PR9 cells; as a control, we have used a
scrambled control siRNA.
In a first experiment, we have evaluated the effect of
HHEX silencing on VEGF-A production and cell growth
of PR9 cells. First, we observed that HHEX silencing
elicited a pronounced decrease of HHEX protein both in
MT and PR9 cells, as shown by Western blotting experi-
ments (Fig. 6a). Then, we showed that HHEX silencing
was able to induce a significant increase of VEGF-A ex-
pression, comparable to that elicited by Zn2+ addition;
the concomitant addition of Zn2+ and HHEX silencing
elicited an additive effect on VEGF-A expression, achiev-
ing a level of expression higher than that observed in
cells undergoing either type of single treatment (Fig. 6b).
In parallel, we have evaluated the effects on PR9 cell
growth and we observed that HHEX silencing mimicked
the stimulatory effect elicited by PML-RARα on the
growth of U-937 cells (Fig. 6c). Combined HHEX silen-
cing and PML-RARα induction did not further stimulate
PR9 cell growth (Fig. 6c).
Fig. 4 Effect of ATO on downmodulation of HHEX expression elicited by PML-RARα induction in PR9 cells (top and middle panels) and on HHEX
expression observed in NB4 cells (bottom panel). Top panels (a, b): PR9 cells have been grown either in the absence (c) or in the presence of
ZnSO4 for 48 h (left and right panels), in the presence of ATO for different times (from 6 to 48 h, right panel), or in the presence of ZnSO4 + ATO
for different time points (from 6 to 48 h, left panel) and HHEX, PML-RARα, or RARα expression were assessed by WB. A representative WB is shown
at the top of each panel and the quantitative evaluation (mean ± SEM in three separate experiments). Bottom panel (c): NB4 cells have been
grown either in the absence (c) or in the presence of ATO for different times (from 6 to 48 h) and HHEX expression was analyzed by WB
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In a second set of experiments, we evaluated the effect
of HHEX silencing on the pro-angiogenetic capacity of
PR9 cells. To this purpose, we evaluated the capacity of
cell culture supernatants of PR9 cells untreated or
treated for 48 h with Zn2+ or of HHEX-silenced cells to
promote tube formation of HUVEC cells. These experi-
ments showed that supernatants of Zn2+-treated or
HHEX-silenced PR9 cells, but not of control PR9 cells,
were able to promote HUVEC tube formation (Fig. 6d).
In a third set of experiments, we evaluated the effect
of HHEX silencing on monocytic differentiation of U-937
cells induced by 1α25OH-VitD3. Previous studies showed
that PML-RARα expression in U-937 cells elicited a
marked inhibition of their capacity to differentiate in
response to 1α25OH-VitD3 [18]. In these experiments,
monocytic differentiation was monitored through the
study of two membrane monocytic markers, CD11b
and CD64, whose expression is strongly induced by
Fig. 5 a Gel shift assay of cellular extracts incubated in vitro with oligonucleotides corresponding to a region of the VEGFR-2 gene promoter
containing two putative HHEX binding sites. In some experiments, labeled oligonucleotide A1P1 containing two HHEX binding sites or labeled
oligonucleotide A2P2 containing one HHEX binding site has been incubated with cellular extracts derived from PR9 cells grown either without
additives (c) or for 24 h in the presence of Zn2+ or Zn2+ + ATRA. The specificity of the bands was tested adding a 100-, 200-, or 300-fold excess
of unlabeled free oligonucleotide probe. b, c HHEX binding to the VEGF (b) and VEGFR-2 (c) promoters as shown by ChIP experiments. Nuclear extracts
derived from PR9 cells grown for 24 h either in the absence (b) or in the presence of ZnSO4 (Zn
2+); cells were crosslinked in vivo; after cell
lysis, chromatin fragments were immunoprecipitated with anti-HHEX antibody; and after DNA purification, DNA regions containing either VEGF
or VEGFR-2 were amplified. In the figure, the VEGF or VEGFR-2 PCR signal without immunoprecipitation is indicated as −A (IgG control) and
after immunoprecipitation as +A (HHEX antibody)
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1α25OH-VitD3. We observed that HHEX silencing
elicited an inhibition of 1α25OH-VitD3-induced mono-
cytic differentiation of U-937 cells, comparable to that
elicited by induction of PML-RARα expression, and silen-
cing of HHEX did not result in a further inhibition of
CD11b and CD64 expression, compared to the values ob-
served with single treatment (Fig. 6e). Furthermore, mor-
phologic analysis showed that, while the large majority of
PR9 cells grown in the presence of 1α25OH-VitD3 ac-
quire the morphology of mature monocytic elements,
PR9 cells treated with Zn2+ or with a HHEX siRNA and
then grown with 1α25OH-VitD3 remained in large part
blocked at a promonocytic stage of cell differentiation
(data not shown).
HHEX overexpression inhibits the pro-angiogenetic and
differentiation blocking effects of PML-RARα
In a fourth set of experiments, we evaluated the effect of
HHEX overexpression on the pro-angiogenetic capacity
of both NB4 and PR9 cells. To this purpose, we evalu-
ated the effect of HHEX overexpression on VEGF-A
mRNA expression and we observed that (a) in NB4 cells,
HHEX overexpression (Fig. 7a) elicited a marked inhibi-
tory effect on VEGF-A mRNA levels, compared to the
levels observed in the same cells transfected with a con-
trol empty vector (Fig. 7b); (b) in PR9 cells transfected
with the HHEX expressing vector (Fig. 8a), Zn2+ addition
elicited a stimulation of VEGF-A mRNA expression mark-
edly lower than in the same cells transfected with the
empty vector (Fig. 8b). HHEX overexpression moderately
reduced the cell growth of both NB4 and PR9 cells, either
when grown in the absence or in the presence of cell dif-
ferentiation inducers, compared to the corresponding
control cells transfected with the empty vector (Figs. 7c
and 8c).
In a fifth set of experiments, we evaluated the effect of
HHEX overexpression on the differentiation capacity of
both NB4 and PR9 cells. In NB4 cells, HHEX overexpres-
sion elicited a moderate, but significant, improvement of
both spontaneous and ATRA-induced granulocytic differ-
entiation, as assessed on the basis of the evaluation of the
expression of CD11b, CD18, CD15, and CD54 membrane
antigens (Fig. 7d).
In PR9 cells transfected with the empty vector (pTWEEN)
PML-RARα expression triggered by Zn2+, a marked in-
hibition of VitD3-induced monocytic differentiation, as
assessed through the analysis of CD11b and CD14 mem-
brane antigens, was observed (Fig. 8d). In PR9 cells
overexpressing HHEX, induction of PML-RARα only
moderately inhibited VitD3-induced monocytic differ-
entiation (Fig. 8d).
Discussion
APL is characterized by the PML/RARα fusion gene
underlying the t(15;17) translocation and resulting in the
formation of the PML-RARα oncoprotein. The molecu-
lar mechanism of leukemic transformation induced by
PML-RARα is largely related to the capacity of this fusion
oncoprotein to act as a potent transcriptional repressor of
RARA and non-RARA target genes, thus interfering with
gene expression programs required for hemopoietic pro-
genitor self-renewal and myeloid cell differentiation [19, 20].
APL blasts are blocked at the promyelocytic stage of
myeloid cell differentiation and two unrelated agents,
ATRA and arsenic trioxide, are able to induce their dif-
ferentiation both in vitro and in vivo. ATRA induces
granulocytic differentiation through a molecular mech-
anism mainly involving transcriptional reactivation of
PML-RARα-silenced genes [21], while ATO acts through
induction of PML/RARα degradation, the clearance of
PML-RARα-bound promoters being sufficient to induce
APL differentiation [22].
In line with these observations, in the present study,
we provided evidence that PML-RARα inhibits HHEX
expression in APL cells. This downmodulation of HHEX
expression, compared to the normal physiological coun-
terpart of APL, was constantly observed in all the 18
primary APLs investigated in the present study. Experi-
ments carried out in U-937 cells expressing inducible
PML-RARα strongly support a direct role of this fusion
protein in inhibiting HHEX expression. The reduced
HHEX expression seems to have two relevant func-
tional consequences in APL cells. First, it seems to be
responsible, at least in part, for the elevated expression
of angiogenetic factors in APLs. This conclusion is sup-
ported by three lines of evidence: in fresh APL blasts,
(See figure on previous page.)
Fig. 6 a, b, c Effect of HHEX silencing on cell proliferation and VEGF-A expression by PR9 cells. MT or PR9 cells have been treated either with a
control siRNA or with a siHHEX RNA and then evaluated for HHEX expression by WB (a), VEGF-A mRNA expression by real-time PCR (b), and cell
proliferation (c). d Effect of HHEX silencing on the capacity of PR9 cells to release pro-angiogenic growth factors. PR9 cells have been treated with
a control siRNA or with siHHEX RNA and then grown for 48 h without (control) or with ZnSO4 (+Zn
2+); cell supernatants were collected and
assayed for their capacity to promote endothelial tube formation using an endothelial tube formation assay using HUVEC cells plated in Matrigel.
As a positive control, HUVEC cells were plated in Matrigel in EGM2 complete medium containing exogenous angiogenetic growth factors. e Effect
of HHEX silencing in the VitD3-induced cell differentiation of PR9 cells. PR9 cells were treated either with control siRNA or with siHHEX RNA and
then grown for 3 days either in the absence (c) or in the presence of 100 μM ZnSO4 (Zn
2+), either in the absence (control) or in the presence of
1α25OH-VitD3 (D3) for 72 h, harvested and then analyzed for the expression of CD11b and CD64 membrane markers by flow cytometry. The results of
one representative experiment are reported in the figure
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we observed a significant inverse correlation between
HHEX and VEGF-A levels; HHEX silencing in PR9
cells mimics the stimulatory effect of PML-RARα on
VEGF-A expression; HHEX overexpression in both NB4
and PR9 cells markedly inhibits PML-RARα-induced
VEGF-A expression. Our observations on the inverse rela-
tionship between HHEX and VEGF-A levels in primary
APL cells were corroborated through the analysis of gene
Fig. 7 Effect of HHEX overexpression on the capacity of NB4 cells to express VEGF-A and to differentiate in response to ATRA. NB4 cells have
been transfected with a control empty vector (pTWEEN) or with this vector containing the human HHEX gene (pHHEX) and then a analyzed for
HHEX expression by Western blotting (top panel, left) and for VEGF-A RNA expression by realtime-PCR (top panel, right); b pTWEEN NB4 cells and
pHHEX NB4 cells have been grown in the absence or in the presence of 1 μM ATRA and evaluated at different times for c the number of viable
cells (middle panels) and for d the expression of CD11b, CD15, CD18, and CD54 membrane antigens (low panels). The results of the three
experiments ± SEM are reported in the figure. For NB4 cells grown in the absence of ATRA, the expression level of CD18 and CD54 antigens
between pTWEEN and pHHEX cells was significant (p≤ 0.05). For NB4 cells grown in the presence of ATRA, the difference of CD15 (p≤ 0.05) and
CD11b, CD18, and CD54 (p≤ 0.01) between pTWEEN and pHHEX cells was significant
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expression data available for various AMLs on the TCGA
platform. Interestingly, this analysis showed also that
among the various AMLs, APLs display the highest
VEGF-A expression and the lowest HHEX/VEGF-A ratio.
These observations further support numerous other litera-
ture data showing a particularly elevated expression of
angiogenetic growth factors in APLs [23–25]. The key and
a direct involvement of HHEX in transcriptional regu-
lation of multiple genes encoding components of the
VEGF signaling pathway, including VEGF, VEGFR-1,
and VEGFR-2, was also shown in a chronic myeloid
leukemia model [26]. It is of interest to note that among
the various AML subtypes, M5 AMLs are characterized
by low HHEX levels and also by increased VEGF-A levels,
although less elevated than in M3 AMLs. An inverse rela-
tionship between HHEX and VEGF-A was observed also
in M5 AMLs. Interestingly, a previous study showed that
M5 AMLs were characterized not only by decreased
HHEX levels but also by a delocalization of HHEX protein
that, at variance with other cell types, is largely confined
to the cytoplasm [27].
The stimulation of an angiogenetic response in APL
cells induced by PML-RARα seems to be relevant for
disease pathogenesis. This conclusion is supported by
Fig. 8 Effect of HHEX overexpression on the capacity of PR9 cells to express VEGF-A and to differentiate in response to VitD3. PR9 cells have been
transfected with a control empty vector (pTWEEN) or with this vector containing the human HHEX gene (pHHEX) and then a analyzed for HHEX
expression by Western blotting (top panel, left) and for VEGF-A RNA expression by realtime-PCR (top panel, right); b pTWEEN PR9 cells and pHHEX
PR9 cells have been treated or not with Zn2+ for 24 h and then grown in the absence or in the presence of 1α25OH-VitD3 and evaluated at dif-
ferent times for the number of viable cells (middle panels) and at day 3 of culture for the expression of CD11 and CD14 membrane antigens (low
panels). The results of the three experiments ± SEM are reported in the figure. For PR9 cells treated with Zn2++VitD3, the difference between
pTWEEN PR9 and pHHEX PR9 cells for both CD11b and CD14 expression was highly significant (p≤ 0.01)
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recent studies showing that angiogenesis inhibitors [28]
and HIF inhibitors [29] impair leukemia progression and
prolong mice survival in APL mouse models.
Second, the reduced HHEX expression induced by
PML/RARα in APL cells seems to play a relevant role in
mediating the inhibitory effect of this fusion protein on
cell differentiation. This conclusion is supported by ex-
periments carried out on NB4 and PR9 cells. As previously
reported, induction of PML-RARα expression in PR9 cells
resulted in a marked inhibition of their capacity to differen-
tiate into monocytes in response to 1α25OH-VitD3 [18].
Interestingly, the silencing in these cells of HHEX expres-
sion by siRNA resulted in an inhibitory effect on 1α25OH-
VitD3-induced cell differentiation, highly comparable
to that induced by PML-RARα. In contrast, HHEX over-
expression in these cells resulted in a partial rescue of the
inhibitory effect elicited by PML-RARα on monocytic
differentiation.
It is of interest to note that recently Kramarzova and
coworkers reported a large screening of homeobox clus-
ter A and B expression at the level of various AML FAB
subtypes and clearly showed that the lowest levels were
observed in FAB M3 AMLs [30]. Particularly, HOXA1,
HOXA5, HOXA6, and HOXB6 expression was low in
APLs [30]. Combined to the findings of the present study,
these observations strongly suggest a general repressive role
of the PML/RARα fusion gene on HOX gene expression.
A low HHEX expression was recently reported also in
AMLs characterized by trisomy 8, the most frequent
chromosome numeric aberration observed in AMLs [31].
The HHEX gene was hypermethylated in trisomy 8
AMLs, a finding in line with the low HHEX expression
observed in these AMLs [31]. In this study, 3 APLs
were studied and all three displayed a hypermethylation
of HHEX gene [31].
The present study contributes in part to clarify the
complex mechanisms through which PML-RARα exerts
its oncogenic potential. In this context, recent studies
highlight a relevant role of some long non-coding RNAs
(lncRNAs) in the mediation of some key pathogenetic
events induced by PML-RARα, particularly at the level
of the control of cell proliferation [32] and of cell differ-
entiation [33].
The identification and characterization of biomarkers
is fundamental in oncology and represents an essential
tool for drug development [34]. At the moment, no data
support a potential role of HHEX as a disease biomarker
for APLs. However, future studies will address this im-
portant issue.
Methods
Human progenitor cell (HPC) purification
Cord blood (CB) was obtained after informed consent
from healthy full-term placentas according to institutional
guidelines. Human CD34+ cells were purified from CB by
positive selection using the midi-MACS immunomagnetic
separation system (Miltenyi Biotec, Bergisch Gladabach,
Germany) according to the manufacturer’s instructions.
The purity of CD34+ cells was assessed by flow cytometry
using a monoclonal PE-conjugated anti-CD34 antibody
and was routinely over 95 % (range comprised between
92–98 %). Purified human hematopoietic progenitor
cells were grown in serum-free medium containing BSA
(10 mg/ml), pure human transferrin (1 mg/ml), human
low-density lipoproteins (40 μg/ml), insulin (10 μg/ml), so-
dium pyruvate (10–4 M), L-glutamine (2 × 10−3 M), rare in-
organic elements (Sn, Ni, Va, Mo, and Mn) supplemented
with iron sulfate (4 × 10−8 M), and nucleosides (10 μg/ml
each). HPCs were induced into specific granulopoietic
differentiation with IL-3 (1 unit/ml), granulocyte/monocyte
CSF (0.1 ng/ml), and saturating amounts of G-CSF
(500 units/ml). The differentiation stage of unilineage
cultures was evaluated by MayGrunwald–Giemsa stain-
ing (Sigma-Aldrich, St. Louis, MO, USA) and cytologic
analysis.
Primary leukemic cells
AML fresh leukemic blasts were isolated from diagnostic
bone marrows obtained from 18 patients with newly di-
agnosed APL, using Ficoll–Hypaque density gradient. The
rapid diagnosis of APL was based on the detection by im-
munofluorescence microscopy of a microspeckled nuclear
pattern that is characteristic of PML protein delocalization
from nuclear bodies in APL. The diagnosis was confirmed
by cytogenetic evidence of the t(15;17)(q22;q21) and/or by
reverse transcription polymerase chain reaction (RT-PCR)
detection of the PML-RARα rearrangement on BM sam-
ples. According to the Declaration of Helsinki, informed
consent was obtained from all patients and healthy donors
and the study was approved by the Institution Review
Board (IRB) of the University of Tor Vergata of Rome,
Italy.
Cell line culture and differentiation
Fresh leukemic blasts were isolated from either bone
marrow (BM) or peripheral blood (PB) by Ficoll–Hypaque
density centrifugation obtained after informed consent
from 18 APL patients classified as M3 by morphological
criteria according to the French–American–British (FAB)
classification. APL cells were grown in the above medium
in the absence (control) or in the presence of ATRA (1 ×
10−6 M; Sigma, St Louis, MO, USA).
The AML cell lines NB4, U937-MT, and U937-PR9
cells (described subclones of the U937 promonocytic cell
line [17]) were grown in RPMI 1640 medium supplemented
with 10 % fetal calf serum in 5 % CO2, 95 % humidified air
at 37 °C. In some experiments, NB4 cells were treated for
3 days with 1 μM ATRA (Sigma). U937-PR9 and U937-MT
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cells were used for induction of PML-RARα expression or
as control, respectively. Cells were cultured either with or
without varying concentrations of ZnSO4 (Sigma), ATRA
(Sigma), or 50 ng/ml 1α250H-Vitamin D3 (Roche, Basel,
Switzerland) for the indicated time points. After different
days of in vitro incubation, cells were harvested and assayed
for cell vitality (by the trypan blue exclusion test) and cell
differentiation. Cell differentiation was assessed by cell
morphology and changes in cell surface antigen expression.
Packaging cell line, 293FT, was maintained in DMEM
(Life Technologies Corporation, Carlsbad, CA, USA)
supplemented with 10 % (v/v) heat-inactivated FBS,
2 mML-glutamine, 100 U/ml penicillin, and 100 ug/ml
streptomycin (Invitrogen).
FACS analysis
Analysis of cell surface antigens was performed by flow
cytometry using a FACScan Flow cytometer (Becton
Dickinson, Bedford, MA, USA). The cells were stained
with a PE-conjugated anti-mouse, CD11b, CD14, CD15,
CD18, CD54, and CD64 antibody (Pharmingen, San
Diego, CA, USA) as previously reported. Briefly, the cells
were incubated for 30 min at 4 °C with an appropriate
dilution of antibody; and after three washings in PBS,
the cells were fixed in PBS formaldehyde (4 %) and ana-
lyzed by flow cytometry. The results were expressed in
terms of the percentage of positive cells and of the mean
fluorescence intensity (MFI).
Western blot analysis
To prepare total extracts, the cells were washed twice
with cold phosphate-buffered saline and lysed on ice
for 30 min with 1 % Nonidet P40 lysis buffer (20 mM
Tris–HCl pH 8.0, 137 mM NaCl, 10 % glycerol, 2 mM
EDTA) in the presence of 1 mM phenymethylsulfonyl
fluoride, 1 mM dithiothreitol, 1 mM sodium orthovana-
date, 2 μg/ml leupeptin, and 2 μg/ml aprotinin. Cell
debris was removed by centrifugation at 10,000 rpm for
10 min at 4 °C, and protein concentration of supernatants
was determined by the Bio-Rad protein assay (Richmond,
CA, USA). Aliquots of cell extracts containing 30–50 μg
of total protein were resolved by 7.5–10 % SDS-PAGE
under reducing and denaturing conditions and transferred
to nitrocellulose filter. The blots were blocked using
5 % non-fat dry milk in TBST (10 mM Tris–HCl
pH 8.0, 150 mM NaCl, 0.1 % Tween 20) for 1 h at room
temperature, followed by incubation with primary anti-
bodies. After washing with TBST, the filters were incubated
with the appropriate horseradish-peroxidase-conjugated
secondary antibodies (Bio-Rad) for 1 h at room
temperature. Immunoreactivity was revealed using an
ECL detection kit (Pierce, USA). In Western blot ex-
periments, the following antibodies were used: HHEX
(Epitomics); VEGFR-2 and RARα (Santa Cruz Biotechnol-
ogy); actin (Oncogene Research Products, Cambridge, MA),
Cell transfection and proliferation
Transient transfections of U937-PR9 cells with siRNA
were carried out using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). Chemically synthesized siRNAs
(Silencer Select Pre-designed and Validated siRNA) to
HHEX, and scrambled siRNAs were purchased from
Ambion and transfected at 10 nM final concentration.
After 24 h, the cells were treated with no additives
(control) or 50 ng/ml VitD3 or 1 μM Zn2+ or both drugs
at the above doses. After 72 h, the expression of HHEX
was assayed by Western blot. Cell growth was analyzed
using Cell Titer-GloMax assay (Promega, Fitchburg, WI,
USA).
Plasmid constructs and lentivirus infection
HHEX complementary DNA (cDNA) (NM_002729) was
synthesized and cloned in Xhol-EcoRV restriction sites
under CMV promoter into a variant third-generation
lentiviral vector, pRRL-CMV-PGK-GFP-WPRE, called Tween
[35], to simultaneously transduce both the reporter GFP and
the gene HHEX. Lentiviral particles were produced in
293FT packaging cell line and infection performed as
previously described [35]. After infection, transduced
cells were selected with green fluorescent protein (GFP)
fluorescence evaluated by FACS analysis.
RNA extraction and analysis
Total RNAs were extracted by the guanidinium iso-
thiocyanate-CsCl method and reverse transcribed using
random primers-RT kit (Invitrogen), according to the
manufacturer’s procedure. The RT-PCR was normalized
for S26 ribosomal protein. The sequences of the oligo-
nucleotide primers used for RT-PCR were as follows:




G-3′ and 5′-TTTTATCGCCCTCAATGTCCAC-3′; VE
GF-A GGCTCTAGATCGGGCCTC and GGCTCTAG
AGCGCAGAGT.
Samples were electrophoresed in 1.5 % agarose gel,
transferred onto Hybond-N (Amersham Pharmacia
Biotech, Uppsala, Sweden) filter and hybridized with
an internal oligomer probe.
Quantitative real-time (qRT)-PCR analysis was per-
formed by TaqMan technology, using the ABI PRISM
7700 DNA Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA). Commercial ready-to-use
primers/probe mixes were used (Assays on Demand Prod-
ucts, Applied Biosystems) for GAPDH, HHEX, VEGF-A
and VEGFR-2, Tie 2, angiopoietin-1, and FGFR-1.
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Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assay was per-
formed according to Upstate Biotechnology protocol
(Lake Placid, NY, USA). Briefly, 5 × 106 cells were cross-
linked in vivo, lysed, and immediately sonicated. Chro-
matin fragments were immunoprecipitated with 4 μg of
anti-HHEX (Epitomics) or anti-RARα (SantaCruz)
antibody; and after treatment with proteinase K for 2 h
at 68 °C, the DNA was purified by phenol/chloroform
extraction and amplified by Hot-start PCR (30 cycles
of 94 °C for 1 min, 60 °C for 1 min, and 72 °C for 1 min)
using the following primers:
VEGFR-2 (FWD) 5′CCTTCTTGGGGCTAGGCAGG
TCACTTCA3′ (−671 to −644), and VEGFR-2 (REV), 5′G
ATCTCCAGCTCCCCAAGCCCATTTA3′ (−148 to −123).
VEGF (FWD) 5′AAAGACCCAACTCAAGTATCATC
TSSAGT3′, and VEGF (REV) 5′CACTCACTGTGTG
TGGCCTTAGGTTATTCAAC3′.
HHEX (FWD) 5′GGTTCAACAGGTTTGTGCAGT3′
and HHEX (REV) 5′CCGGCTATCAGAAGTCGAGTG3′.
EMSA
The double-stranded HHEX binding sites (400 ng) were
labeled with [α32]P dATP using Klenow enzyme. The
following sequences in the VEGFR-2 receptor promoter








The binding-reaction mixture (20-μl final volume) con-
tained labeled oligonucleotide probes (10,000 cpm) in
binding buffer (75 mM KCI, 20 mM Tris–HCl (pH 7.5),
1 mM dithiothreitol) containing 5 μg of bovine serum al-
bumin per milliliter, 14 % (vol/vol) glycerol, and 3 μg of
poly(dI-dC). Total cell lysates (10 μg) were added, and
the reaction mixture was incubated for 20 min at room
temperature. Samples were electrophoresed in a 5 %
poly-acrylamide gel in 0.5× Tris-borate-EDTA (TBE)
buffer for 2 h at 200 V at 18 °C. The gels were then
dried and subjected to autoradiography. Competition
studies were performed by adding unlabeled double-
stranded oligonucleotides at a 100-, 200-, and 300-fold
molar excess over the labeled probe.
Analysis of TCGA data
Gene expression analysis data from AML samples were
collected as previously described (The Cancer Genome
Atlas Research Network 2008). Processed data sets were
obtained directly from the public access data portal
(http://cancergenome.nih.gov/dataportal/data/about);
176 AML samples stratified by leukemia French American
British morphology classification (FAB) and a total of
20,319 genes with expression values in the RPKM format
were included. The expression levels of HHEX and
VEGF-A of the 179 samples from 6 FAB categories
were plotted. Data sets were cross-referenced using
tumor-specific identification numbers.
Matrigel in vitro HUVEC tube formation assay
PR9 cells treated in different conditions, as reported in
the corresponding section “Results”, have been grown
for 48 h, and the conditioned media were collected, cen-
trifuged, transferred to fresh tubes, and stored at −20 °C.
Growth factor-reduced Matrigel (100 μl), after being
thawed on ice, was plated in a 96-well cell culture plate.
The chamber was then incubated at 37 °C for 30 min to
allow the Matrigel to polymerize. HUVEC maintained in
complete EGM2 medium and starved for 4 h were tryp-
sinized and seeded (2 × 104 cells/well) in each well with
100 μl of conditioned medium. EGM2 complete medium,
supplemented with endothelial growth factors, was used
as a positive control, while EM2 medium without growth
factors was used as a negative control. The multiwell
plates were incubated for 24 h and then tube formation
was analyzed through inspection using and inverted
microscope equipped with a digital camera.
Statistical analysis
Data were analyzed using parametric statistics with one-
way analysis of variance (ANOVA). Post hoc tests included
the Student’s t test and the Tukey multiple comparison
tests as appropriate using Prism (GraphPad, San Diego,
CA, USA). Data are presented as mean value ± SEM from
three independent experiments. Significance was set at
p < 0.05.
Conclusions
HHEX downmodulation induced by PML-RARα is a key
event during APL pathogenesis and is physiopathologi-
cally relevant to mediate the inhibitory effect on cell dif-
ferentiation and the pro-angiogenetic effects elicited by
this oncogenic fusion protein.
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